Fenwick & West represented Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, in its initial public offering for $52 million. The company priced 6,500,000 shares of its common stock at a price to the public of $8.00 per share.
Jefferies LLC and Leerink Partners LLC acted as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. acted as co-managers.
The Fenwick transaction team included corporate attorneys Robert Freedman, Cindy Hess, Effie Toshav, Dawn Belt, Julia Forbess, William Black, Seth Oranburg and Lara Muller; executive compensation and employee benefits attorney Shawn Lampron; and technology transactions attorney Spencer Glende.